Scientists have characterized the role of thousands of mutations in the BRCA2 cancer gene, findings that may help reassure ...
Financial writer discusses MGX's gene editing technology, cash runway, and lack of clinical data for potential future ...
The early stage company is developing a new approach to gene editing to treat rare genetic diseases. It does this using mRNA, ...
Intellia Therapeutics, Inc. shares declined over 5% on Monday morning after Morgan Stanley downgraded the stock to ‘Equal ...
DeepSeek was tasked with selecting two stocks investors can buy now and hold long-term due to their growth potential.
Leerink Partnrs boosted their FY2024 earnings per share (EPS) estimates for CRISPR Therapeutics in a note issued to investors ...
This new tool, known as minimal, versatile genetic perturbation technology (mvGPT), combines the powers of gene editing, ...
Functional genomics can help deconvolute the link between genotype and phenotype in disease, revealing new drug targets and ...
As translational CRISPR-based research continues to make waves in laboratories and the clinic, scientists across life science disciplines pursue out-of-the-ordinary genome editing applications. From ...
The field of cancer research is rapidly evolving, with a growing focus on the intersection of cancer immunology, gene editing, and epigenetics. This ...
It's the start of a new year, and that makes now the perfect time to load up on stocks that could boost your portfolio in ...
New research shows that female mice expressing only a maternal X chromosome experience faster brain aging and cognitive ...